Discontinued — last reported Q3 '24
Baqsimi — Revenue
Eli Lilly Baqsimi — Revenue increased by 8.1% to $13.40M in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 2.3%, from $13.10M to $13.40M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market adoption or successful commercialization, while a decrease may signal product maturity, increased competition, or a strategic shift in the company's portfolio focus.
Detailed definition
This metric represents the total gross sales generated from the specific pharmaceutical product line designated as Baqsi...
Peer comparison
Comparable to specific product-level revenue disclosures in other pharmaceutical companies, often categorized under specialty therapeutics or diabetes management segments.
lly_segment_baqsimi_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q2 '22 | Q3 '22 | Q2 '23 | Q3 '23 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $28.30M | $28.30M | $28.30M | $29.00M | $43.00M | $613.90M | $13.10M | $12.40M | $13.40M |
| QoQ Change | — | +0.0% | +0.0% | +2.5% | +48.3% | >999% | -97.9% | -5.3% | +8.1% |
| YoY Change | — | — | — | +2.5% | +51.9% | >999% | -69.5% | -98.0% | +2.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's baqsimi — revenue?
- Eli Lilly (LLY) reported baqsimi — revenue of $13.40M in Q3 2024.
- How has Eli Lilly's baqsimi — revenue changed year-over-year?
- Eli Lilly's baqsimi — revenue increased by 2.3% year-over-year, from $13.10M to $13.40M.
- What does baqsimi — revenue mean?
- The total amount of money earned from sales of the Baqsimi product.